Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the Clinic

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 01 Nov, 15:59 UTC

Setara Biosciences’ lead program is a potential treatment for the rare neuromuscular disorder Charcot-Marie-Tooth disease type 2C and the prevalent condition overactive bladder. This small molecule came from Actio Biosciences, which was recently acquired by Jazz Pharmaceuticals. The post Rare…

science

Sources

• T2Rare Disease Biotech Setara Starts Out With $90M and a Lead Drug in the ClinicFierce Biotech / Fierce Healthcare / MedCity / GEN01 Nov, 15:59